Patient demographics
| Characteristic . | Values for patients (N = 76) . |
|---|---|
| Age at diagnosis, median (range), y | 72.1 (34-86) |
| Female sex | 38 (51) |
| Performance status | |
| 0-1 | 53 (84) |
| ≥2 | 9 (16) |
| Missing | 13 |
| Disease category | |
| De novo | 59 (78) |
| Secondary | 9 (12) |
| Therapy related | 8 (11) |
| Cytogenetics | |
| Normal | 61 (80) |
| Other intermediate | 9 (12) |
| Adverse | 2 (2.6) |
| Failed | 4 (5.3) |
| FLT3 ITD | 18 (24) |
| FLT3 TKD | 11 (14) |
| DNMT3A mutation∗ | 19 (31) |
| IDH1 mutation∗ | 6 (9.8) |
| IDH2 mutation∗ | 12 (20) |
| KRAS or NRAS mutation∗ | 7 (11) |
| TP53 mutation∗ | 2 (3.3) |
| Therapy | |
| Azacitidine | 47 (62) |
| Decitabine | 2 (2.6) |
| Low-dose cytarabine | 27 (36) |
| Best morphologic response | |
| CR | 72 (95) |
| CRi | 4 (5.3) |
| Allogeneic transplant | |
| In first CR | 4 (5.3) |
| After relapse | 5 (6.6) |
| No transplant | 67 (88) |
| Characteristic . | Values for patients (N = 76) . |
|---|---|
| Age at diagnosis, median (range), y | 72.1 (34-86) |
| Female sex | 38 (51) |
| Performance status | |
| 0-1 | 53 (84) |
| ≥2 | 9 (16) |
| Missing | 13 |
| Disease category | |
| De novo | 59 (78) |
| Secondary | 9 (12) |
| Therapy related | 8 (11) |
| Cytogenetics | |
| Normal | 61 (80) |
| Other intermediate | 9 (12) |
| Adverse | 2 (2.6) |
| Failed | 4 (5.3) |
| FLT3 ITD | 18 (24) |
| FLT3 TKD | 11 (14) |
| DNMT3A mutation∗ | 19 (31) |
| IDH1 mutation∗ | 6 (9.8) |
| IDH2 mutation∗ | 12 (20) |
| KRAS or NRAS mutation∗ | 7 (11) |
| TP53 mutation∗ | 2 (3.3) |
| Therapy | |
| Azacitidine | 47 (62) |
| Decitabine | 2 (2.6) |
| Low-dose cytarabine | 27 (36) |
| Best morphologic response | |
| CR | 72 (95) |
| CRi | 4 (5.3) |
| Allogeneic transplant | |
| In first CR | 4 (5.3) |
| After relapse | 5 (6.6) |
| No transplant | 67 (88) |
ITD, internal tandem duplication; TKD, tyrosine kinase domain.
Data are given as number (percentage) unless otherwise indicated.
Next-generation sequencing results available in 61 patients.